The phase 3 JAVELIN200 study failed to show an improvement in the addition of avelumab to PLD via PFS in recurrent platinum-resistant EOC [41]; however, a dual biomarker analysis suggested a possible benefit of the combination in the subgroup of patients with PD-L1 positive (≥1% tumor cell, ≥5% immune cells or both) and CD8 positive (≥1% immune cells) tumors, warranting further exploration in future trials [41]. This evidence concerns the gene CD8A and neoplasm.